Sign in
WithdrawnPhase 1

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Key facts

Who runs it
Ossium Health, Inc.
Trial code
Status
Withdrawn
Phase
Phase 1
Started
Sept 2022
Ended
Nov 2024
Type of study
Interventional, 3 groups
Treatments tested
  • Cyclophosphamide
  • Fludarabine
  • Total Body Irradiation
  • Busulfan
  • Mesna
  • Sirolimus
  • Mycophenolate Mofetil
  • Filgrastim
  • Bone Marrow Transplant
Record updated
24 February 2026
Why it stopped
Change in Study Design

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 45 criteriaShow less

Who can take part

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥ 18 and < 71 years (Note: HIV-negative subjects with MDS must be aged <50 at the time of signing the informed consent form)
  • Diagnosed with
  • Acute leukemias or T-lymphoblastic lymphoma (T-LBL) in 1st or subsequent CR
  • Acute lymphocytic leukemia (ALL) or T-LBL as defined by the following:
  • < 5% blasts in the bone marrow
  • Normal maturation of all cellular components in the bone marrow
  • No currently active extramedullary disease (EMD) (e.g., central nervous system (CNS), soft tissue disease)
  • ANC ≥ 1,000/mm3
  • Acute myeloid leukemia (AML) defined by the following:
  • < 5% blasts in the bone marrow
  • No blasts with Auer rods
  • Normal maturation of all cellular components in the bone marrow
  • No currently active EMD (e.g., CNS, soft tissue disease)
  • ANC ≥ 1,000/mm3
  • Acute biphenotypic leukemia (ABL)/Acute undifferentiated leukemia (AUL) defined by the following:
  • < 5% blasts in the bone marrow
  • Normal maturation of all cellular components in the bone marrow
  • No currently active EMD (e.g., CNS, soft tissue disease)
  • ANC ≥ 1,000/mm3
  • Myleodysplastic Syndromes (MDS), fulfilling the following criteria:
  • Subjects with de novo MDS who have or have previously had Intermediate-2 or High-risk disease as determined by the IPSS. Current Intermediate-2 or High- risk disease is not a requirement
  • Subjects must have < 20% bone marrow blasts, assessed within 60 days of informed consent
  • Subjects may have received prior therapy for the treatment of MDS prior to enrollment
  • Performance status: Karnofsky ≥ 60%
  • Adequate organ function defined as:
  • Cardiac: LVEF at rest ≥ 35% (RIC cohort) or LVEF at rest ≥ 40% (FIC cohort), or LVFS ≥ 25%
  • Pulmonary: DLCO, FEV1, FVC ≥ 50% predicted by pulmonary function tests (PFTs). DLCO value may be corrected or uncorrected for hemoglobin
  • Hepatic: total bilirubin ≤ 2.5 mg/dL, and ALT, AST, and ALP < 5 x ULN (unless ALT, AST, and/or ALP are disease related)
  • Renal: SCr within normal range for age (see table 5.1B). If SCr is outside normal range for age, CrCl > 40 mL/min/1.73m2 must be obtained (measured by 24-hour (hr) urine specimen or nuclear glomerular filtration rate (GFR), or calculated GFR (by Cockcroft-Gault formula)
  • Subjects must have the ability to give informed consent according to applicable regulatory and local institutional requirements
  • Availability of deceased HLA MMUD cryopreserved product through Ossium cryobank
  • HLA MMUD defined as 4-7/8 HLA-allele matching at MHC class (A, B, or C) or MHC class II (DRB1)
  • Additional MHC class II HLA (DP and DQ) typing will be collected, but not incorporated in donor selection

Who cannot take part

  • Autologous HCT < 3 months prior to the time of signing the informed consent form
  • Treatment with an investigational drug or other interventional GVHD clinical trials
  • Current uncontrolled bacterial, viral or fungal infection (currently taking medication with evidence of progression of clinical symptoms or radiologic findings)
  • Prior allogeneic HCT
  • Any condition(s) or diagnosis, both physical or psychological, or physical exam finding that in the investigator's opinion precludes participation
  • Subjects with MDS may not receive RIC and must be < 50 years of age at the time of signing the informed consent form
  • Pediatric patients (17 years or younger)
  • Suitable HLA-matched related or 8/8 allele matched (HLA-A, -B, -C, -DRB1) unrelated donor excluding Ossium product
  • Pregnancy or lactation
  • Primary myelofibrosis or myelofibrosis secondary to essential thrombocythemia or polycythemia vera

About the trial

What the trial wants to find out

Multicenter single arm study to assess the safety and efficacy of allogeneic transplantation using cryopreserved bone marrow from deceased MMUD and PTCy, sirolimus and MMF for GVHD prophylaxis.

The 3 groups in the trial

  • Regmin A (RIC)Other group

    Pre-transplant conditioning treatment with Fludarabine, Cyclophosphamide, and Total Body Irradiation (TBI)

    Treatment: Cyclophosphamide, Fludarabine, Total Body Irradiation, Mesna, Sirolimus, Mycophenolate Mofetil, Filgrastim, and Bone Marrow Transplant

  • Regimen B (FIC)Other group

    Pre-transplant conditioning treatment with Busulfan and Cyclophosphamide OR Fludarabine

    Treatment: Cyclophosphamide, Fludarabine, Busulfan, Mesna, Sirolimus, Mycophenolate Mofetil, Filgrastim, and Bone Marrow Transplant

  • Regimen C (FIC)Other group

    Pre-transplant conditioning treatment with Cyclophosphamide and Total Body Irradiation (TBI)

    Treatment: Cyclophosphamide, Total Body Irradiation, Mesna, Sirolimus, Mycophenolate Mofetil, Filgrastim, and Bone Marrow Transplant

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
PRESERVE: A Multi-Center Trial Using Banked, Cryopreserved HLA-Mismatched Unrelated Donor Bone Marrow and Post-Transplantation Cyclophosphamide in Allogeneic Transplantation for Patients With Hematologic Malignancies
Record updated
24 February 2026